Loading asset research
Atara Biotherapeutics Inc. Common Stock
ATRANasdaq · USD · StocksQuote as of · Exchange session not verified$8.81
+3.16%
Today
ATRA
Loading 1D prices…
Market cap
$87.4M
Volume
31.2K
52w high
$19.1552w low
$3.92Company profile
Atara Biotherapeutics Inc. Common Stock
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Sector
Health Care
Industry
Biological Products, (No Diagnostic Substances)
Exchange
Nasdaq
Display currency
USD
Location
THOUSAND OAKS, CA, United States
Employees
10
Fiscal year end
1231
CIK
1604464
Session & valuation
Open$8.60
Previous close$8.54
Day high$8.99
Day low$8.53
30-day avg. volume46.2K
Outstanding shares10M
Diluted EPS$2.57
Latest annual period
P/E (trailing)3.43
P/E (forward)5.63
Price / book-2.22
Beta0.11
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2836
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| PTHSPelthos Therapeutics Inc. Common Stock | $86.2M | $16.8M | -257.93% | -$23.04 | -0.94% | Buy |
| CGTXCognition Therapeutics Inc. Common Stock | $91.2M | $0.00 | — | -$0.32 | +0.17% | Buy |
| CRDFCardiff Oncology Inc. Common Stock | $97.2M | $593K | -7.73% | -$0.69 | -3.12% | Buy |
| KLRSKalaris Therapeutics Inc. Common Stock | $73.6M | $0.00 | — | -$2.85 | -4.89% | Buy |
| OKYOOKYO Pharma Limited Ordinary Shares | $71.4M | $0.00 | — | -$0.24 | 0.00% | Buy |